<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200249</url>
  </required_header>
  <id_info>
    <org_study_id>RADICAL</org_study_id>
    <nct_id>NCT03200249</nct_id>
  </id_info>
  <brief_title>Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal Cancers</brief_title>
  <acronym>RADICAL</acronym>
  <official_title>Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal Cancers: Phase 2 Study (RADICAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis : Therapeutic intensification by increasing the dose delivered to the tumor by
      RCMI (conformational radiotherapy by intensity modulation) in order to reduce local relapse,
      often associated with poor prognosis

      Primary objective: evaluate the rate of tumor sterilization and the toxicities of RTCT with
      concomitant boost in intensity modulation in patients with rectal cancer CT3-T4 and / or
      cN1-2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete histological response rate</measure>
    <time_frame>at 8 weeks after inclusion</time_frame>
    <description>Absence of residual cancer cells on the final analysis of the tumor and lymph node</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>at 1, 2, 3, 4, 5 and 13 weeks after inclusion and at 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36 months after surgery</time_frame>
    <description>Toxicity is assessed according to the NCI-CTCAE toxicity scale version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Advanced Rectal Cancers</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Treatment : concomitant preoperative radio-chemotherapy (during 5 weeks)
Chimiotherapy: Capecitabine 1600 mg/m2/j ; 5/7 days during the 5 weeks of radiotherapy
Radiotherapy RT + SIB-IMRT (5 weeks ; 5 sessions/week ; 25 sessions): Pelvic prophylactic dose of 45 Gy (1,8 Gy/session); &quot;boost&quot; with a dose of 60 Gy on the tumor PTV (2,4 Gy/session) - Total dose: 60 Gy in 25 sessions during 5 weeks.
- TME surgery (8 weeks after the end of treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative chemo-radiation with IG-IMRT dose escalation</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adenocarcinoma of the rectum cT3 or cT4 or cN+, M0 and for which CPR recommends
             preoperative radiochemotherapy

          2. Tumor &lt;15 cm of the anal margin in rigid or subperitoneal rectoscopy at the MRI

          3. Tumor potentially resectable from the outset, or considered to be resectable after
             radiochemotherapy

          4. Operable Patient

          5. Age between 18 and 75

          6. OMS performance status 0-2

          7. No co-morbidity likely to prevent the delivery of treatment

          8. Adequate contraception for men, and for non-menopausal women

          9. Neurotrophic neutrophils 1500 / mm3, platelets 100 000 / mm3, and hemoglobin 10 g / dL

         10. Bilirubin ≤ 1.5 times the upper limit of normal (LNS), ASAT and ALAT ≤ 1.5LNS,
             Alkaline phosphatase ≤ 1.5 LNS

         11. Creatinine clearance&gt; 50 mL / min

         12. Patient must have been informed and must have signed the specific informed consent
             form.

         13. Patient must be affiliated to a Social Health Insurance.

        Exclusion Criteria:

          1. Remote metastasis

          2. Cancer not resectable

          3. Contraindication to capecitabine and its excipients

          4. Previous history of pelvic radiotherapy or previous chemotherapy

          5. History of inflammatory bowel or rectum disease

          6. History of angina pectoris monitored or myocardial infarction or heart failure

          7. Active active infection or other serious underlying condition that may prevent the
             patient from receiving treatment

          8. Other concomitant cancer, or history of cancer other than in situ cancer of the
             treated cervix or basal cell carcinoma or squamous cell carcinoma

          9. Patient already included in another therapeutic trial with an experimental molecule

         10. Pregnant woman, likely to be pregnant or nursing

         11. Persons deprived of their liberty or under guardianship

         12. Patient unable to comply with the required medical follow-up for geographic, social or
             psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>03 80 73 75 00</phone>
    <email>ERederstorff@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilles CREHANGE</last_name>
    <email>gcrehange@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Berardino DE BARI</last_name>
      <email>bdebari@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Alexis LEPINOIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles CHEHANGE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Berardino DE BARI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Gf Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles CHEANGE, MD</last_name>
      <email>gcrehange@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles CHEANGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali QUIVRIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali ROUFFIAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David THIBOUW</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dose escalation, chemo-radiation, rectum cancer, phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

